Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of ALXN1720 in Healthy Subjects
NCT04920370Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Sep 2019
- Primary completion
- Nov 2021
- Modality
- Bispecific Antibodies, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gefurulimab in myasthenia gravis (MG) (5 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Incidence of Treatment-emergent and Serious Adverse Events up to 176 days. Started Sep 2019; status: completed.
02
Drugs
gefurulimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04920370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04920370.